Skip to main content

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

Written by Customer Service on . Posted in Public Companies.

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief Financial Officer.  Interim CFO, David Socks, will continue with the company as a strategic advisor and remain a member of the Board of Directors.Mr. Branning was most recently with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) where he served as Senior Vice President and Chief Financial Officer.  He brings a diverse global finance background consisting of over 25 years of experience in corporate finance and accounting, tax, financial planning and analysis, and investor relations.“I am delighted to welcome Todd to Phathom and to have him join our executive leadership team.  As we continue to grow our organization and prepare for the potential commercialization of vonoprazan, Todd’s expertise in finance and accounting will add great value to our company,” said Terrie Curran, President and Chief Executive Officer of Phathom.  “I would also like to thank David for his many contributions to Phathom and am excited that we will continue to benefit from his expertise in business development and his involvement in other key strategic areas.”Mr. Branning has extensive finance experience in the pharmaceutical industry.  As SVP, CFO at Amneal Pharmaceuticals, he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger in May 2018.  Prior to Amneal Pharmaceuticals, he served as Senior Vice President, Chief Financial Officer for Teva Pharmaceuticals’ (NYSE: TEVA) Global Generic Medicines division.  Mr. Branning led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva’s largest multi-billion dollar commercial unit.  Prior to joining Teva in 2016, he served as Vice President, Finance, for Allergan plc.  Mr. Branning has also served in financial leadership roles at PricewaterhouseCoopers, PPG Industries, Inc. and Merck & Co., Inc.Mr. Branning holds an MBA degree from Carnegie Mellon University and a BBA from the University of Miami.  He is a Certified Public Accountant and has completed a CFO certification program from The Wharton School at the University of Pennsylvania.  About Vonoprazan
Vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown the potential to have rapid, potent, and durable anti-secretory effects as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. The U.S. Food and Drug Administration (FDA) has designated vonoprazan as a qualified infectious disease product (QIDP) and awarded Fast Track status for the treatment of H. pylori infection in combination with both amoxicillin and clarithromycin and with amoxicillin alone. Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda, which completed 18 Phase 3 trials for vonoprazan and received marketing approval in 13 countries in Asia and Latin America.About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma.CONTACTS
Joe Hand
1-877-742-8466
info@phathompharma.comMedia Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.comInvestor Contact:
Patti Bank
Westwicke Partners
415-513-1284
patti.bank@westwicke.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.